Shin Fujisawa

3.8k total citations
182 papers, 2.2k citations indexed

About

Shin Fujisawa is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Shin Fujisawa has authored 182 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Hematology, 53 papers in Genetics and 48 papers in Oncology. Recurrent topics in Shin Fujisawa's work include Acute Myeloid Leukemia Research (53 papers), Hematopoietic Stem Cell Transplantation (50 papers) and Chronic Myeloid Leukemia Treatments (42 papers). Shin Fujisawa is often cited by papers focused on Acute Myeloid Leukemia Research (53 papers), Hematopoietic Stem Cell Transplantation (50 papers) and Chronic Myeloid Leukemia Treatments (42 papers). Shin Fujisawa collaborates with scholars based in Japan, United States and India. Shin Fujisawa's co-authors include Yoshiaki Ishigatsubo, Heiwa Kanamori, Katsumichi Fujimaki, Naoto Tomita, Rika Sakai, Hiroyuki Fujita, Masatsugu Tanaka, Jun Taguchi, Hirotaka Takasaki and Fumio Kodama and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Cell Biology and Blood.

In The Last Decade

Shin Fujisawa

171 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shin Fujisawa Japan 27 1.1k 572 561 410 380 182 2.2k
Eva van den Berg Netherlands 28 846 0.8× 648 1.1× 367 0.7× 452 1.1× 711 1.9× 88 2.6k
Anne Huynh France 28 1.6k 1.5× 593 1.0× 499 0.9× 175 0.4× 625 1.6× 130 2.7k
Pietro Pioltelli Italy 23 969 0.9× 319 0.6× 778 1.4× 302 0.7× 195 0.5× 80 2.0k
Benet Nomdedeu Spain 22 881 0.8× 349 0.6× 829 1.5× 592 1.4× 361 0.9× 88 1.8k
T Hotta Japan 23 495 0.5× 554 1.0× 390 0.7× 453 1.1× 392 1.0× 131 1.8k
Sanam Loghavi United States 31 1.5k 1.4× 721 1.3× 851 1.5× 662 1.6× 826 2.2× 226 2.9k
Koiti Inokuchi Japan 28 1.2k 1.1× 525 0.9× 687 1.2× 302 0.7× 740 1.9× 145 2.2k
Norifumi Tsukamoto Japan 25 826 0.8× 433 0.8× 561 1.0× 706 1.7× 381 1.0× 139 2.1k
Francesco Onida Italy 31 1.7k 1.6× 643 1.1× 1.3k 2.3× 571 1.4× 506 1.3× 118 3.0k
Wolfram Ebell Germany 28 938 0.9× 605 1.1× 320 0.6× 426 1.0× 823 2.2× 85 2.9k

Countries citing papers authored by Shin Fujisawa

Since Specialization
Citations

This map shows the geographic impact of Shin Fujisawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shin Fujisawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shin Fujisawa more than expected).

Fields of papers citing papers by Shin Fujisawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shin Fujisawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shin Fujisawa. The network helps show where Shin Fujisawa may publish in the future.

Co-authorship network of co-authors of Shin Fujisawa

This figure shows the co-authorship network connecting the top 25 collaborators of Shin Fujisawa. A scholar is included among the top collaborators of Shin Fujisawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shin Fujisawa. Shin Fujisawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miyazaki, Takuya, Hiroyuki Takahashi, Takaaki Takeda, et al.. (2025). Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma. Internal Medicine. 64(18). 2716–2722. 2 indexed citations
2.
3.
Ishii, Yoshimi, Shin Fujisawa, Takuya Miyazaki, et al.. (2024). Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia. International Journal of Hematology. 121(2). 187–193. 4 indexed citations
4.
Toya, Takashi, Masatoshi Sakurai, Jun Kato, et al.. (2023). Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis. Blood Advances. 8(5). 1084–1093. 4 indexed citations
5.
Fujisawa, Shin, Masatsugu Tanaka, Maki Hagihara, et al.. (2023). Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: A multicenter retrospective study. Hematological Oncology. 42(1). e3228–e3228. 2 indexed citations
6.
Ebina, Toshiaki, Haruka Hirose, Yuki Nakajima, et al.. (2023). Echocardiographic Findings of Malignant Lymphoma with Cardiac Involvement: A Single-center Retrospective Observational Study. Internal Medicine. 63(3). 359–364. 2 indexed citations
7.
Kurosawa, Saiko, Takuhiro Yamaguchi, Takehiko Mori, et al.. (2022). Health-related QOL challenges and coping ability of patients after treatment for acute leukemia: qualitative analysis. 11(3). 177–186.
8.
Kurosawa, Saiko, Takuhiro Yamaguchi, Takehiko Mori, et al.. (2021). Prevalence of organ symptoms in allo-HCT survivors and their impact on work and daily life. 10(4). 172–182. 1 indexed citations
9.
Konuma, Takaaki, Tadakazu Kondo, Masayoshi Masuko, et al.. (2021). Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. Bone Marrow Transplantation. 56(11). 2779–2787. 9 indexed citations
10.
Sasaki, Haruka, Koichi Murakami, Akira Nishiyama, et al.. (2021). Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients. Scientific Reports. 11(1). 18046–18046. 6 indexed citations
11.
Shimizu, Hiroaki, Noriko Doki, Heiwa Kanamori, et al.. (2019). Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant. Bone Marrow Transplantation. 54(12). 2020–2026. 2 indexed citations
12.
Najima, Yuho, Chikashi Yoshida, Noriyoshi Iriyama, et al.. (2018). Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study. Leukemia Research. 66. 66–72. 29 indexed citations
13.
14.
Fujisawa, Shin, Taisei Suzuki, Jun Aoki, et al.. (2017). Clinical Impact of Sarcopenia and Skeletal Muscle Mass Change during Chemotherapy on Outcomes of Diffuse Large B-Cell Lymphoma. Blood. 130. 5221–5221. 1 indexed citations
15.
Tomita, Naoto, Shin Fujisawa, Chizuko Hashimoto, et al.. (2014). Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma. Annals of Hematology. 94(3). 431–436. 18 indexed citations
16.
Yamazaki, Etsuko, Naoto Tomita, Satoshi Koyama, et al.. (2014). Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type. Medical Oncology. 31(9). 149–149. 15 indexed citations
17.
Nakajima, Yuki, Hideyuki Kuwabara, Yukako Hattori, et al.. (2013). Successful treatment of a pregnant woman with Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematology. 97(3). 427–429. 4 indexed citations
18.
19.
Maruta, A, Minoru Yoshida, Rika Sakai, et al.. (2001). Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplantation. 27(3). 307–310. 72 indexed citations
20.
Fujisawa, Shin, Hiroaki Fujita, Tadahide Noguchi, et al.. (1992). [Malignant histiocytosis associated with central neurological symptoms and cerebrospinal fluid involvement].. PubMed. 33(7). 981–5.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eva van den Berg Breakdown of academic impact, for papers by Anne Huynh Breakdown of academic impact, for papers by Pietro Pioltelli Breakdown of academic impact, for papers by Benet Nomdedeu Breakdown of academic impact, for papers by T Hotta Breakdown of academic impact, for papers by Sanam Loghavi Breakdown of academic impact, for papers by Koiti Inokuchi Breakdown of academic impact, for papers by Norifumi Tsukamoto Breakdown of academic impact, for papers by Francesco Onida Breakdown of academic impact, for papers by Wolfram Ebell
Rankless by CCL
2026